What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide and lidocaine
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names lidocaine in its drug interactions section; the lidocaine labels PlainMeds reads (4) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide. The cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label: “Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA.”
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the lidocaine FDA label on DailyMed (effective May 13, 2024, Fresenius Kabi USA, LLC).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about lidocaine?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↑ antiarrhythmics ↑ digoxin; Clinical Comment: Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What does the lidocaine label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Lidocaine's label (effective May 13, 2024) and its 3 other brand-application labels do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xylocaine MPF), Fresenius Kabi USA, LLC, effective May 13, 2024 (SPL set d5e0d06f-ba1e-44d4-aa89-39d6c146dc23), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Lidocaine | |
|---|---|---|
| Labeled for | HIV | Pain |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $143.35 per tablet Genvoya tablet | $0.154 per gram 5% ointment |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once